Last €0.32 EUR
Change Today 0.00 / 0.00%
Volume 0.0
LYF On Other Exchanges
Symbol
Exchange
London
Berlin
OTC US
As of 2:08 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

ekf diagnostics holdings plc (LYF) Snapshot

Open
€0.32
Previous Close
€0.32
Day High
€0.32
Day Low
€0.32
52 Week High
01/22/14 - €0.44
52 Week Low
07/25/13 - €0.26
Market Cap
133.8M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
422.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EKF DIAGNOSTICS HOLDINGS PLC (LYF)

Related News

No related news articles were found.

ekf diagnostics holdings plc (LYF) Related Businessweek News

No Related Businessweek News Found

ekf diagnostics holdings plc (LYF) Details

EKF Diagnostics Holdings plc is engaged in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the United Kingdom, the United States, Germany, Poland, Russia, Ireland, and Asia. The company offers near patient analyzers for the measurement of glucose, lactate, hemoglobin, hematocrit, and HbA1c. Its products include glycated hemoglobin analyzers, such as Quo-Test, Quo-Lab, and Biosen HbA1c analyzers for monitoring diabetes; hemoglobin analyzers consisting of Hemo Control and Hemo Vet, which are point of care devices to provide results for hemoglobin and hematocrit, as well as STAT-Site M Hgb, a hand-held device for blood screening programs; and glucose analyzers comprising Biosen C-Line and S-Line glucose and lactate analyzers, and Lactate Scout+, a hand-held lactate analyzer. The company also provides rapid testing services, including pregnancy tests, such as True20, QuPID, and QuStick for urine only or urine and serum pregnancy testing; and infectious diseases tests, such as H. Pylori, RELY Mono, RELY and Strep A, and QuStick for the detection of pathonogenic micro-organisms, such as bacteria, parasites, viruses, and fungi. In addition, it offers clinical chemistry reagents; and biomarker diagnostic kits used by researchers and clinicians, as well as molecular diagnostic test kits, which are focused on applications within oncological research. The company sells its products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

330 Employees
Last Reported Date: 02/26/14
Founded in 1990

ekf diagnostics holdings plc (LYF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 297.0K GBP
Executive Chairman
Total Annual Compensation: 45.0K GBP
Chief Financial Officer, Secretary and Execut...
Total Annual Compensation: 19.0K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 214.0K GBP
Compensation as of Fiscal Year 2013.

ekf diagnostics holdings plc (LYF) Key Developments

EKF Diagnostics Holdings plc Signs Distribution Contract with Tianjin Multiclone Trading Company

EKF Diagnostics Holdings plc has signed a new distribution contract for Biosen C-Line, its glucose and lactate analyser, with Tianjin Multiclone Trading Company in China, which could significantly increase its installed user base. The initial contract is for 1,900 analysers worth approximately €4.0 million over a two and a half year period, commencing immediately. The end customer will also need to purchase consumables for the analyser, and it is anticipated that this could generate a further €2.0m of revenue over the same forecast period. Furthermore, whilst these initial revenue expectations are extremely pleasing, it is expected that these instruments will have a useful life of up to 10 years, which would significantly increase the consumables revenue for EKF.

EKF Diagnostics Holdings plc Appoints Tito Bacarese-Hamilton to the Board of Directors as Chief Technology Officer

EKF Diagnostics Holdings plc announced the appointment of Dr. Tito Bacarese-Hamilton to the Board of Directors of the company, as Chief Technology Officer with immediate effect. Tito joins EKF from Diabetes specialist LifeScan Scotland Ltd. ("Lifescan"), a wholly owned Johnson & Johnson franchise, where he was Vice President, R&D for New Products & Platforms.

EKF Diagnostics Holdings plc Announces Board Changes

EKF Diagnostics Holdings plc announced that Mr. Paul Foulger, who re-joined the Board as Interim Finance Director in July 2013, has agreed to join the Company on a permanent basis with effect from 11 April 2014. The company announced that Mr. Gordon James Hall has agreed to step down as Non-Executive Director with effect from 31 March 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LYF:GR €0.32 EUR 0.00

LYF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LYF.
View Industry Companies
 

Industry Analysis

LYF

Industry Average

Valuation LYF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 1.9x
Price/Cash Flow 68.8x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKF DIAGNOSTICS HOLDINGS PLC, please visit www.ekfdiagnostics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.